What Matters
What Matters
What Matters
Atia Vision’s OmniVu™
Modular Shape-Changing Intraocular Lens (IOL)
Modular Shape-Changing Intraocular Lens (IOL)
Aims to deliver a premium solution that utilizes the natural accommodative mechanism of the eye to restore the full range of functional vision, with minimal visual disturbances, for cataract patients.
Strives to Achieve Refractive Predictability
with consistent and reproducible patient outcomes
Aspires to Restore Full Functional Range
to improve near, intermediate, and distance visual acuity
Aims to Preserve Natural Vision Quality
while reducing visual disturbances*
*Commonly reported with currently-available advanced technology IOLs
OmniVu’s proprietary design aims to provide stable, predictable refractive outcomes.
The dual-optic IOL features a shape-changing, fluid-filled base and fixed power front optic that are paired to achieve the desired refractive outcome.
Using conventional surgical techniques, the base is positioned into the capsular bag and the fixed power optic is then implanted and docked into the base.
Disclaimer: Investigational Use Only. Not available for sale in any geography.
Clinical Need
Cataracts are a common vision impairment that, if left untreated, lead to vision loss and blindness as the clouding of the natural crystalline lens progresses.
While the most commonly used intraocular lenses (IOLs) provide distance correction, patients receiving these lenses often require glasses for good near vision.
There is a large unmet need for an IOL that provides visual correction, from distance to near, without the side effects of halos, glare, and difficulty seeing in dimly lit environments.
News
FDA Grants Atia Vision Approval to begin US Clinical Trial of OmniVu™ Lens System in Patients with Cataracts
CAMPBELL, CA – May 20, 2025 – Atia Vision, Inc., a Shifamed portfolio company, today announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin a traditional feasibility clinical study of its OmniVu™ Lens System. This novel intraocular lens is designed to restore dynamic range of vision following cataract surgery, going beyond the capabilities of current presbyopia-correcting lenses.
Atia Vision Announces Presentation of First-In-Human Results with Their Novel Intraocular Lens at American Society of Cataract Refractive Surgery (ASCRS) Annual Meeting
CAMPBELL, CA – May 5, 2023 – Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a modular shape-changing intraocular lens (IOL), today announced the first clinical data about their patented OmniVu™ IOL System will be presented at the 2023 Annual Meeting of the American Society of Cataract Refractive Surgery (ASCRS) in San Diego, California.
Atia Vision, a Shifamed Portfolio Company, to Close on $42m Series E Financing
CAMPBELL, CA – August 2, 2022 – Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a modular presbyopia-correcting intraocular lens (IOL), announced today the first close of a $42M Series E financing. Led by Cormorant Asset Management, with participation by The Capital Partnership (TCP), PA MedTech VC Fund, AMED Ventures and Shifamed angel investors, funds will be used to expand the company’s clinical program, scale its manufacturing capabilities, and expand the Atia Vision team.
- World Health Organization. Blindness and vision impairment.
- American Academy of Ophthalmology. Eye health statistics.
Investigational Use Only. Not available for sale in any geography.
Atia, Atia Vision, Truly Insightful, the Atia logo and all product and service names are trademarks of Atia Vision, Inc. unless otherwise noted. No use is permitted without prior written authorization.
© 2023 Atia Vision, Inc. All rights reserved.
Atia Vision, Inc.
550 Division Street
Campbell, CA 95008
info@atiavision.com